ArticleInternational journal of nanomedicine2026
CD71-Targeted and ROS-Responsive Micelles for Homoharringtonine Delivery to Enhance Therapeutic Efficiency Against FLT3-ITD Acute Myeloid Leukemia.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) subtype of acute myeloid leukemia (AML) is associated with poor clinical outcomes. Homoharringtonine (HHT), a natural protein inhibitor, has shown strong activity against FLT3-ITD AML. However, its clinical use is limited by rapid clearance and systemic toxicity. To address these limitations, a CD71-targeted, ROS-responsive micelle (TDTP/HHT) was developed for precise and efficient HHT delivery. Methods: CD71 expression was assessed in AML patient samples and cell lines. TDTP/HHT was prepared by self-assembly using a D-peptide ligand ( Results: Cytotoxicity analysis revealed that FLT3-ITD AML is intrinsically sensitive to HHT. Analysis of patient samples and cell lines revealed high CD71 expression and elevated ROS levels in AML, most predominantly in the FLT3-ITD subtype. The designed TDTP/HHT showed prolonged circulation time, ROS-responsive drug release, and stable targeting capacity. It did not compete with endogenous transferrin for binding sites but instead demonstrated transferrin-promoted cellular uptake. Both in vitro and in vivo studies confirmed that TDTP/HHT significantly inhibited the growth of FLT3-ITD AML cells. Mechanistically, TDTP/HHT suppressed multiple key downstream signaling proteins of FLT3-ITD. In addition, the system also remained active in CD71-high FLT3-WT AML cells, although higher HHT concentrations were required. Conclusion: This study presents a novel targeted nanodrug that exploits the intrinsic HHT sensitivity of FLT3-ITD AML cells and their characteristic high CD71 expression and elevated ROS levels. Therefore, this platform is particularly suited for the treatment of FLT3-ITD AML while potentially applicable to other AML subtypes with high CD71 expression. By enabling specific intracellular accumulation of HHT and multitarget inhibition of FLT3 signaling pathways, this system achieves enhanced anti-AML efficacy both in vitro and in vivo, offering strong potential for future clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.